Tirzepatide Sigma: Separating the Lab Chemical from the Licensed Medicine

The misconception: 'Sigma tirzepatide' as a cheaper way to access the drug

The biggest misunderstanding behind this search is the idea that research-catalogue tirzepatide (most commonly the Sigma-Aldrich listing) represents a cheaper, prescription-free route to the same active ingredient found in Mounjaro. It does not. Sigma-Aldrich and comparable chemical suppliers produce tirzepatide as an analytical or pharmacological research tool: typically a lyophilised peptide powder, sold in microgram quantities, for in vitro or animal research. The purity specifications, excipients, sterilisation processes and dosing formats are entirely different from those of a licensed medicinal product. There is no reliable way for a non-specialist to reconstitute, dose or administer such a compound safely. Equally, buying any injectable substance for self-injection outside a licensed supply chain removes the clinical safeguards that make a medicine safe in practice, prescriber oversight, patient-specific dosing, monitoring for interactions and side effects.

The MHRA has issued repeated public warnings about unlicensed and counterfeit injectable weight-loss products circulating online, some of which have caused serious harm. Approximately 20 million doses of illegally traded weight-loss medicines, with an estimated street value of around £45 million, were seized during 2025 enforcement operations alone. Reporting suspect sellers is possible via the MHRA Yellow Card scheme, which handles both adverse reactions and concerns about product legitimacy.

What tirzepatide actually is, and what the licensed product contains

Mounjaro is a dual agonist of the GIP and GLP-1 receptors: the only medicine in the UK that activates both pathways simultaneously. GIP and GLP-1 are gut hormones involved in appetite signalling, satiety and blood-glucose regulation. By engaging both receptors, tirzepatide slows gastric emptying and reduces appetite more reliably than single-pathway approaches. Each Mounjaro KwikPen holds four weekly doses and is available in UK strengths ranging from 2.5 mg to 15 mg. Treatment begins at 2.5 mg (a dose chosen specifically to help the body adjust before therapeutic doses are reached) and is titrated by the prescriber, typically in four-week steps. More on how Mounjaro works, its storage requirements and what the pen itself looks like is covered in detail on our Mounjaro page.

In clinical trials, participants taking tirzepatide 30 mg lost an average of around 20–21% of body weight over 72 weeks, according to the SURMOUNT-1 trial published in the New England Journal of Medicine. Those figures come from a tightly controlled study with monitored dosing and clinical oversight, conditions that do not exist outside a legitimate prescribing relationship.

Who can access licensed tirzepatide in the UK, and through which routes

Under its UK licence, tirzepatide is approved for adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present, such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. NICE also recommends tirzepatide for NHS use through a phased rollout targeting adults with a BMI of 35 or above alongside weight-related comorbidities, per NICE technology appraisal TA1026. NHS access remains restricted to specific cohorts as the rollout progresses.

Private prescribing is the route available to people who do not meet current NHS criteria, or who prefer not to wait. That means a consultation with a registered prescriber, clinical assessment and (if approved) a genuine Mounjaro pen from a GPhC-registered pharmacy. If you are wondering what private treatment costs in practice, the guide to Mounjaro pricing in the UK covers what is typically included and what to watch for. When sourcing any prescription medicine online, the safest first step is to check the pharmacy against the GPhC register. A pharmacy that cannot be verified there should not be trusted with a prescription medicine.

What to expect if you start licensed tirzepatide treatment

Once a prescriber approves treatment, the practical reality is straightforward. The pen is cold-chain dispatched and arrives with DPD in plain, unbranded packaging, you can track it to the hour on your phone. Side effects are common early on, particularly gastrointestinal ones: nausea, loose stools, indigestion and fatigue are the most frequently reported, especially after a dose increase. They tend to ease as the body adjusts over the first couple of weeks. Serious effects are rarer; pancreatitis is a known but infrequent risk, severe, persistent stomach pain that reaches the back should prompt urgent medical attention. A fuller picture of what to expect, including injection-site guidance and storage, is set out on the tirzepatide side effects page.

The prescriber-led model matters here. Anyone comparing a research peptide listing with a licensed medicine pen is comparing very different things: one has no clinical oversight, no verified purity controls and no legal status as a medicine. If you are weighing up whether Mounjaro or tirzepatide under another route is the right fit for you, speaking to a qualified prescriber is the right first move, not a laboratory supplier catalogue. Our weight-loss treatment overview outlines the options available through a regulated UK pharmacy, and our clinical team reviews every consultation personally before any prescription is written.